Status:
COMPLETED
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
Lead Sponsor:
AstraZeneca
Conditions:
Stable Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by p...
Eligibility Criteria
Inclusion
- Patients with documented stable Coronary Artery Disease (CAD) (stable angina, previous MI history, previous history of revascularization)
- Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception
Exclusion
- History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (CABG))
- Any acute or chronic unstable condition in the past 30 days
- Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma
- History of intolerance or allergy to aspirin or clopidogrel
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00642811
Start Date
May 1 2008
End Date
March 1 2009
Last Update
October 4 2011
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Jonesboro, Arkansas, United States
2
Research Site
Ormond Beach, Florida, United States
3
Research Site
Baltimore, Maryland, United States
4
Research Site
Cincinnati, Ohio, United States